Ursem Stan, Francic Vito, Keppel Martin, Schwetz Verena, Trummer Christian, Pandis Marlene, Aberer Felix, Grübler Martin R, Verheyen Nicolas D, März Winfried, Tomaschitz Andreas, Pilz Stefan, Obermayer-Pietsch Barbara, Heijboer Annemieke C
Department of Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, Vrije Universiteit Amsterdam, Endocrine Laboratory, Amsterdam, Netherlands.
Division of Endocrinology and Diabetology, Department of Internal Medicine, Endocrinology Lab Platform, Medical University of Graz, Graz, Austria.
Endocr Connect. 2019 May 1;8(5):518-527. doi: 10.1530/EC-19-0097.
PTH can be oxidised in vivo, rendering it biologically inactive. Non-oxidised PTH (n-oxPTH) may therefore give a better image of the hormonal status of the patient. While vitamin D supplementation decreases total PTH (tPTH) concentration, the effect on n-oxPTH concentration is unexplored. We investigated the effect of vitamin D on n-oxPTH concentration in comparison to tPTH and compared the correlations between parameters of calcium, bone and lipid metabolism with n-oxPTH and tPTH.
N-oxPTH was measured in 108 vitamin D-insufficient (25(OH)D <75 nmol/L) hypertensive patients, treated with vitamin D (2800 IE daily) or placebo for 8 weeks in the Styrian Vitamin D Hypertension Trial (NCT02136771). We calculated the treatment effect and performed correlation analyses of n-oxPTH and tPTH with parameters of calcium, bone and lipid metabolism and oxidative stress.
After treatment, compared to placebo, 25(OH)D concentrations increased, tPTH decreased by 9% (P < 0.001), n-oxPTH by 7% (P = 0.025) and the ratio of n-oxPTH/tPTH increased (P = 0.027). Changes in phosphate and HDL concentration correlated with changes in n-oxPTH, but not tPTH.
tPTH and n-oxPTH decrease upon vitamin D supplementation. Our study suggests that vitamin D supplementation reduces the oxidation of PTH, as we observed a small but significant increase in the non-oxidised proportion of PTH upon treatment. In addition, we found that changes in phosphate and HDL concentration showed a relationship with changes in n-oxPTH, but not tPTH. This may be explained by the biological activity of n-oxPTH. Further research should be carried out to establish the clinical relevance of n-oxPTH.
甲状旁腺激素(PTH)在体内可被氧化,从而使其失去生物活性。因此,非氧化型PTH(n - oxPTH)可能能更好地反映患者的激素状态。虽然补充维生素D会降低总PTH(tPTH)浓度,但对n - oxPTH浓度的影响尚不清楚。我们研究了维生素D对n - oxPTH浓度的影响,并与tPTH进行比较,同时比较了钙、骨和脂质代谢参数与n - oxPTH和tPTH之间的相关性。
在施蒂里亚维生素D高血压试验(NCT02136771)中,对108例维生素D不足(25(OH)D <75 nmol/L)的高血压患者进行了n - oxPTH检测,这些患者接受维生素D(每日2800国际单位)或安慰剂治疗8周。我们计算了治疗效果,并对n - oxPTH和tPTH与钙、骨、脂质代谢及氧化应激参数进行了相关性分析。
治疗后,与安慰剂组相比,25(OH)D浓度升高,tPTH降低9%(P < 0.001),n - oxPTH降低7%(P = 0.025),n - oxPTH/tPTH比值升高(P = 0.027)。磷酸盐和高密度脂蛋白(HDL)浓度的变化与n - oxPTH的变化相关,但与tPTH无关。
补充维生素D后,tPTH和n - oxPTH均降低。我们的研究表明,补充维生素D可减少PTH的氧化,因为我们观察到治疗后PTH的非氧化比例有小幅但显著的增加。此外,我们发现磷酸盐和HDL浓度的变化与n - oxPTH的变化有关,而与tPTH无关。这可能由n - oxPTH的生物活性来解释。应开展进一步研究以确定n - oxPTH的临床相关性。